Hershey (HSY) Sees 10% Revenue Growth Driven by GLP-1 Drug Impact

Hershey (HSY) reported a revenue increase of over 10% in the first quarter, driven by higher sales in its mints and gum categories due to increased GLP-1 drug usage. Ice Breakers, their third-largest confection brand, alone saw retail sales rise over 8%. Despite this sales boost, HSY shares fell more than 2% in morning trading. The market's mixed reaction could reflect broader concerns about consumer spending and the impacts of medication on purchasing behaviors.